Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31461381 | 0.80 | CYP11B1 (0.36) | — | |
| SCHEMBL18325700 | 0.75 | HCAR2 (0.45) | HCAR2HRH2HRH3 | |
| SCHEMBL11667139 | 0.70 | HCAR2 (0.41) | HCAR2HRH2HRH3 | |
| SCHEMBL8283481 | 0.69 | HCAR2 (0.82) | HCAR2 | |
| SCHEMBL26924565 | 0.68 | HCAR2 (0.32) | HCAR2 | |
| SCHEMBL1006964 | 0.67 | DHODH (0.47) | HCAR2 | |
| SCHEMBL4753717 | 0.67 | HCAR2 (0.44) | HCAR2 | |
| SCHEMBL20184283 | 0.67 | P2RX7 (0.33) | — | |
| SCHEMBL4753322 | 0.67 | CYP1A2 (0.46) | HCAR2CYP1A2CYP2C19 | |
| SCHEMBL26255987 | 0.67 | CYP1A2 (0.42) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2008148832-A1 | COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEROF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | HCAR2 4707/4885CYP1A2 782/4885CYP2C19 391/4885 |
| US-10202353-B2 | Therapeutic compounds | RPL35, SARS1, HAVCR2 | HCAR2 4740/4885CYP1A2 903/4885CYP2C19 575/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HCAR2 3961/4885CYP1A2 489/4885CYP2C19 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.